Recent Research into the Histone Deacetylase 2 - Pipeline Review, H1 2016

Histone Deacetylase 2(Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)- Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted pipeline therapeutics.

The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Histone Deacetylase 2 - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1-Associated Factor 1 or EC 3.5.1.98)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
Companies Mentioned

4SC AG Acetylon Pharmaceuticals, Inc. Chipscreen Biosciences Ltd Curis, Inc. GlaxoSmithKline Plc HitGen LTD Italfarmaco S.p.A. MEI Pharma, Inc. Merck & Co., Inc. Rodin Therapeutics Sigma-Tau S.p.A. TetraLogic Pharmaceuticals Yungjin Pharm. Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###